New drug combo shows promise for Tough-to-Treat ovarian cancer
Disease control
Completed
This early-stage trial tested a new drug called SL-172154 combined with either standard chemotherapy or a targeted therapy in 86 people with ovarian cancer that stopped responding to platinum-based chemo. The main goals were to check safety and find the best dose. Researchers als…
Phase: PHASE1 • Sponsor: Shattuck Labs, Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC